481 studies whose primary subject is psilocybin have been published so far in 2026. Newest first. Back to the psilocybin overview
JAMA Psychiatry October 21, 2026 Ellen Bradley, Parker Kelley, Balázs Szigeti et al.
This nonrandomized clinical trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress in people with Parkinson disease and mood dysfunction.
Therapeutics October 19, 2026 Lukasz Szarpak, Michal Pruc, Dorota Jablonska-Moczulo et al.
Background/Objectives: Treatment-resistant depression (TRD) is heterogeneous and recurrent. Psilocybin administered with structured psychological support can reduce symptoms rapidly. Support protocols differ in content and intensity, and trial design complicates estimates of the specific drug effect and durability. We reviewed efficacy, durability, mechanisms, safety, and clinical delivery in...
Psychopharmacology October 19, 2026 Landon M. Klein, Jared M. Kopelman, Richard F Sharp et al.
Classical psychedelic drugs such as the tryptamine psilocybin can alter temporal perception. Previously, the phenylethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, altered timing precision and accuracy in mice performing the discrete-trials temporal discrimination task (TDT), a retrospective timing task where subjects differentially respond depending on...
Psychopharmacology October 17, 2026 Sixtine Fleury, Yian Shang, Katherine M. Nautiyal
Psilocybin can produce rapid and sustained antidepressant-like and anxiolytic effects, yet the receptor and circuit mechanisms underlying these behavioral changes remain unclear. While the serotonin 2A receptor mediates psilocybin's acute psychedelic effects, psilocin (the active metabolite of psilocybin) binds many serotonin receptor subtypes. Our prior work has identified the serotonin 1B...
CNS & Neurological Disorders - Drug Targets October 14, 2026 Sheekha Chaudhary, Sanchit Dhankhar, Monika Saini et al.
More than fifty million individuals worldwide are experiencing neurodegenerative disorders, which include Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, and frontotemporal dementia. These disorders have a significant role in the gradual degradation of cognition and motor skills. Most current treatment approaches have little...
Current Neuropharmacology October 14, 2026 Mareli Vázquez-Barreto, Mariana Ugarte-Rocha, Abraham Flores Vargas et al.
Mental disorders are among the leading causes of non-fatal health loss worldwide and are associated with significant individual, social, and economic burdens. On the other hand, neuropathic pain affects approximately 7-8% of the world's adult population and is a leading reason for medical consultations. A bidirectional relationship between depression and pain has been widely documented....
Zenodo (CERN European Organization for Nuclear Research) October 14, 2026 Cacho Ernesto preprint
As psilocybin-assisted therapy becomes increasingly standardized in measuring short-term clinical outcomes, the processes that follow the psychedelic experience remain far less defined. This paper examines integration, aftercare, and long-term follow-up from clinical trials to real-world implementation in Oregon and Colorado, identifying critical gaps and opportunities to better understand,...
October 14, 2026 Dayne Rayford, Shivani Dayal, Kosu Boudreau et al. preprint
Background and aimsPsilocybin can induce profound alterations in perception, emotion and self-referential processing. These changes are often accompanied by increased feelings of interpersonal connection, found via both psychometric survey data and anecdotally collected qualitative data. Despite recent increases in psychedelic research and treatment, most clinical trials have been performed in...
bioRxiv (Cold Spring Harbor Laboratory) October 14, 2026 Greg Cooper, Devon Stoliker, Sebastian Vincent Astl Delgado et al. preprint
Language helps organise experience into an idiosyncratic, temporally extended sense of self. We therefore used fMRI to investigate whether greater similarity between participants in the activity of language-associated brain regions accompanied psilocybin-induced loss of selfhood. Participants heard music and viewed moving clouds at baseline and after 19 mg psilocybin. At each brain location and...
Frontiers in Psychiatry October 14, 2026 Mathieu Seynaeve, Leonie Schneider, Ian Roullier et al.
BackgroundWhile psychedelic treatments for difficult-to-treat mental health conditions are advancing, participant perspectives remain under-explored. This study examined former participants’ experiences across recruitment, preparation, dosing, integration and study ending, and generated recommendations for future trials and treatment delivery.MethodsThis qualitative descriptive study, informed...
Psychopharmacology October 13, 2026 Marisa J. Savini, Kylie M. King, Lillianna P. Puppel et al.
Abstract: Rationale: Psychedelics are considered to be promising therapeutic agents that could effectively treat several psychological disorders. However, these compounds can exert acute adverse effects that limit their practicality. Objectives: Across three experiments, the present study examined the acute and delayed effects of psilocybin (PSIL) and its putatively non-hallucinogenic analog,...
Behavioural Pharmacology October 13, 2026 Bart A. Ellenbroek, Beth Naylor, Jiun Youn
Psilocybin has emerged as a promising therapeutic agent, with clinical benefits attributed to enhanced neuroplasticity rather than acute pharmacological effects. However, the fundamental mechanisms underlying these effects remain poorly understood. Using planarians as a model system, we investigated whether psilocybin enhances associative learning using a conditioned place preference paradigm....
ACS Omega October 9, 2026 Evangelos Dadiotis, Romanos Konstantinos Antonopoulos, Antigoni Cheilari et al.
Abstract The genus Psilocybe (Basidiomycota) comprises over 300 mushroom-forming species, many of which produce the secondary metabolite psilocybin, a prodrug of its dephosphorylated active metabolite psilocin. Psilocybin has recently attracted significant interest, with numerous active, recruiting, and completed clinical trials registered on ClinicalTrials.gov, primarily investigating its...
Journal of Psychopharmacology October 8, 2026 Gianluca A. Florineth, Anna L. Boeker, Tobias Bracht et al.
Background: Psilocybin-assisted therapy (PAT) has emerged as a promising intervention for alcohol use disorder (AUD), yet contemporary clinical evidence has not been systematically synthesized to validate its clinical utility and safety profile. Methods: Contemporary clinical trials of PAT for AUD were identified systematically from PubMed, PsycINFO, and Scopus by two independent reviewers....
Frontiers in Psychiatry October 8, 2026 Anthony L. Back, Cynthia J. Price, Bonnie A. Mcgregor et al.
Cancer patients arrive for psilocybin therapy with bodies altered by illness and treatment — bodies that they have learned to brace against, dissociate from, or scan for threat. Research on psilocybin-assisted therapy for cancer-related depression and anxiety consistently identifies the quality of the acute subjective experience — reflected in constructs such as acceptance, surrender,...
OSF Preprints October 7, 2026 Suzanne Grant, Maria González, Hannah Adler preprint
The objective of this scoping review is to map the extent, range, and types of evidence related to psilocybin-assisted psychotherapy in people with cancer, including the types of psychotherapy used, models of delivering therapy, and associated outcomes, as reported in qualitative and quantitative studies.
Psychological Medicine October 6, 2026 Avery Chan Eun, Kevin H. Yang, Joseph J Palamar
Psilocybin use has increased in the US alongside promising therapeutic potential for depression, raising concerns that individuals may forgo conventional mental health treatment for unsupervised psilocybin use. However, no nationally representative studies have examined whether psilocybin use is associated with differential treatment utilization or perceived unmet need for mental health care...
Research Square October 5, 2026 Anette Kjellgren, Johan Lundberg, Hampus Yngwe et al. preprint
Abstract Psilocybin treatment has emerged as a promising intervention for Major Depressive Disorder (MDD). However, the contribution of psychotherapeutic support to treatment outcomes remains unclear. This study explored therapists' descriptions of their work during a randomized, double-blind, placebo-controlled psilocybin treatment phase II trial for MDD. Nine therapists participated in...
medRxiv October 5, 2026 Praachi Tiwari, Sandeep M. Nayak, Nathan D. Sepeda et al. preprint
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or...
Journal of Psychiatric Research October 1, 2026 Erica Kaczmarek, Sabrina Wong, Noah Chisamore et al.
Background Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in MDD, however, its effects on anhedonia specifically have yet to be systematically reviewed. This review evaluates available clinical and pre-clinical research, exploring...